Business Context and Reporting Period
This Form 8-K, filed on November 14, 2023, by Graphite Bio, Inc. (the "Registrant"), announces the entry into a definitive merger agreement with Lenz Therapeutics, Inc. ("LENZ"). The transaction involves a reverse merger where a Graphite subsidiary will merge with LENZ, with LENZ surviving as a wholly-owned subsidiary. The combined entity will operate under the name "LENZ Therapeutics, Inc." and will be listed on The NASDAQ Global Market.
Key Financial Metrics and Transaction Terms
- Valuation: The transaction values Graphite at $126.5 million and LENZ at $231.6 million.
- Ownership Structure: On a pro forma basis, pre-Merger LENZ stockholders will own approximately 65% of the combined company, while pre-Merger Graphite stockholders will own approximately 35% (excluding the PIPE investment).
- Concurrent PIPE Investment: Graphite has agreed to sell shares to PIPE Investors for an aggregate purchase price of $53.5 million. The minimum required is $50 million, with an option to increase up to $125 million.
- Cash Dividend: Graphite expects to declare a cash dividend of $60 million to pre-Merger Graphite stockholders, subject to adjustment.
- Liquidity Requirement: A closing condition requires Graphite's net cash at Closing, after the dividend, to be no less than $115 million.
- Termination Fees: Either party may be required to pay a termination fee of $7.5 million under specified circumstances.
Material Changes and Corporate Actions
The filing details a material change in control and corporate structure. Key changes include:
- Name Change: Graphite Bio, Inc. will change its name to "LENZ Therapeutics, Inc."
- Stock Split: Graphite will effect a reverse stock split of its common stock at a ratio to be mutually agreed upon.
- Board Composition: The post-merger board will consist of seven members: five designated by LENZ and two by Graphite.
- Equity Adjustments: Graphite stock options with an exercise price of $3.00 or greater will accelerate and be cancelled if unexercised; options below $3.00 will continue under existing terms.
Guidance, Outlook, and Risks
Management anticipates the merger to qualify as a tax-free reorganization. The combined company intends to advance product candidates and build commercial infrastructure. The filing includes extensive forward-looking statements regarding clinical timelines, regulatory approvals, and cash runway, noting that actual results may differ materially.
Key Risks and Contingencies:
- Closing Conditions: The merger is subject to stockholder approvals from both companies, expiration of the HSR Act waiting period, Nasdaq listing approval, and the effectiveness of a Form S-4 registration statement.
- Financing Risk: Closing is contingent on the execution of the PIPE investment (minimum $50 million).
- Operational Risks: Risks include the failure to obtain regulatory approval for product candidates, delays in clinical trials, and the inability to secure additional capital.
- Exchange Ratio Adjustments: The ownership percentages may be adjusted based on Graphite's net cash position at closing relative to the $175 million benchmark.
Investor Verification Checklist
- Verify the final Exchange Ratio and ownership percentages once Graphite's net cash at closing is confirmed.
- Confirm the successful execution of the PIPE investment and the final amount raised (minimum $50 million required).
- Review the upcoming Form S-4 Proxy Statement for detailed risk factors and voting instructions.
- Monitor the status of stockholder approvals from both Graphite and LENZ.
- Assess the impact of the $60 million cash dividend on Graphite's remaining liquidity and the combined company's cash runway.